Moleculin Biotech, Inc. (NASDAQ:MBRX) to Post Q1 2024 Earnings of ($3.59) Per Share, Roth Capital Forecasts

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at Roth Capital decreased their Q1 2024 earnings estimates for Moleculin Biotech in a report released on Monday, March 25th. Roth Capital analyst J. Aschoff now expects that the company will earn ($3.59) per share for the quarter, down from their prior forecast of ($2.40). The consensus estimate for Moleculin Biotech’s current full-year earnings is ($10.27) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q2 2024 earnings at ($2.82) EPS, Q3 2024 earnings at ($2.41) EPS, Q4 2024 earnings at ($2.53) EPS, FY2024 earnings at ($11.05) EPS, FY2025 earnings at ($8.35) EPS, FY2026 earnings at ($7.35) EPS and FY2027 earnings at $1.83 EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Moleculin Biotech in a report on Thursday, December 14th. Maxim Group dropped their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday. Finally, StockNews.com started coverage on shares of Moleculin Biotech in a report on Thursday. They issued a “sell” rating for the company.

Moleculin Biotech Price Performance

Shares of MBRX stock opened at $5.54 on Thursday. Moleculin Biotech has a twelve month low of $4.34 and a twelve month high of $24.75. The company’s 50-day moving average price is $7.88 and its 200-day moving average price is $8.23.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its stake in Moleculin Biotech by 19.2% during the first quarter. State Street Corp now owns 71,397 shares of the company’s stock worth $127,000 after buying an additional 11,497 shares during the period. Renaissance Technologies LLC boosted its stake in Moleculin Biotech by 79.3% during the first quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock worth $107,000 after buying an additional 26,500 shares during the period. Charles Schwab Investment Management Inc. purchased a new position in Moleculin Biotech during the fourth quarter worth about $39,000. Atticus Wealth Management LLC purchased a new position in Moleculin Biotech during the fourth quarter worth about $43,000. Finally, Citadel Advisors LLC purchased a new position in Moleculin Biotech during the fourth quarter worth about $55,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.